410 Is a Single Dose, Single Agent Peri-Operative Antibiotic Protocol Adequate for Endoscopic Endonasal Skull Base Surgery? A 14-Year Review of 574 Cases

Abstract

Abstract Post-operative meningitis is a rare but potentially fatal complication of endoscopic endonasal skull base surgery. As endonasal approaches to the skull base are clean-contaminated procedures, peri-operative antibiotics are routinely used. We sought to analyse the safety and efficacy of a single agent, single dose protocol in cases of endonasal anterior skull base surgery. Database of all endonasal anterior skull-base procedures performed in ENT Department at Leeds General Infirmary between 2008 and February 2022 was prospectively recorded. The primary outcome measure was development of meningitis within 30-days of surgery. Our protocol uses single dose of IV co-amoxiclav 1.2g (or teicoplanin if allergy precludes co-amoxiclav). The data was further divided according to primary or revision surgery, the presence or absence of intra-operative CSF leak, and the development or not of a post-operative CSF leak. Over the 14-year period, 574 endoscopic endonasal operations that fulfilled inclusion criteria were performed. The overall rate of post-operative meningitis across the entire cohort was 2.6%(n = 15). Among the 15 cases:80% (12/15) had intra-operative CSF leak47% (7/15) were revision cases73% (11/15) had extended endoscopic approach as pathology that required an intentional opening of the arachnoid80% (12/15) had post-operative CSF LeakThere were no cases of meningitis following repair of long-standing CSF fistula or encephalocele and surgery for sinonasal tumours with skull-base involvement. In conclusion, a single dose of 1.2g intravenous co-amoxiclav (or teicoplanin) is safe in the context of sellar-centred pathologies, repair of pre-existing spontaneous CSF leaks, and surgery on sinonasal tumours with skull base involvement.